Treatment of the Hutchinson-Gilford Progeria Syndrome With a Combination of Pravastatin and Zoledronic Acid
Status:
Completed
Trial end date:
2013-07-01
Target enrollment:
Participant gender:
Summary
We suggest treating the Hutchinson-Gilford Progeria Syndrome by two molecules (zoledronic
acid and pravastatin).The therapeutic approach which we propose has for objectives to reduce,
to prevent or to delay the gravest infringements of the disease, to prolong the life of the
children, and in a more general way, aim at improving their living conditions.